SCOPUS 정보 검색 플랫폼

Volumn 55, Issue 4, 2014, Pages 929-931

Simplification of risk stratification for splenic marginal zone lymphoma: A point-based score for practical use

(18) Montalban, Carlos a Abraira, Victor b,c Arcaini, Luca d Domingo Domenech, Eva e Guisado Vasco, Pablo f Iannitto, Emilio g Mollejo, Manuela h Matutes, Estella i Ferreri, Andres J M j Salar, Antonio k Rattotti, Sara d Carpaneto, Andrea l Perez, Ricardo m Bello, Jose Luis n Hernandez, Miguel o Caballero, Dolores p Carbonell, Felix q Piris, Miguel A r

a MD ANDERSON CANCER CENTER (Spain)

b HOSPITAL RAMÓN Y CAJAL (Spain)

c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP (Spain)

d FONDAZIONE IRCCS POLICLINICO SAN MATTEO (Italy)

e HOSPITAL DURAN I REYNALS (Spain)

f HOSPITAL QUIRÓN (Spain)

g SG Moscati Hospital (Italy)

h HOSPITAL VIRGEN DE LA SALUD (Spain)

i ROYAL MARSDEN HOSPITAL (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

HUMAN; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SPLENIC MARGINAL ZONE LYMPHOMA; CANCER GRADING; CANCER STAGING; LYMPHOMA, B-CELL, MARGINAL ZONE; MORTALITY; PROGNOSIS; SPLENIC NEOPLASMS;

HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; SPLENIC NEOPLASMS;

EID: 84904349741 PISSN: 10428194 EISSN: 10292403 Source Type: Journal
DOI: 10.3109/10428194.2013.818143 Document Type: Letter

Times cited : (37)

References (12)

1
- 53249123632
- World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press;
- Swerdlow SH, Campos E, Harris NL, et al. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
- (2008) Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues
- Swerdlow, S.H.¹ Campos, E.² Harris, N.L.³

2
- 40749143143
- Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria
- DOI 10.1038/sj.leu.2405068, PII 2405068
- Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008;22:487-495. (Pubitemid 351386718)
- (2008) Leukemia , vol.22 , Issue.3 , pp. 487-495
- Matutes, E.¹ Oscier, D.² Montalban, C.³ Berger, F.⁴ Callet-Bauchu, E.⁵ Dogan, A.⁶ Felman, P.⁷ Franco, V.⁸ Iannitto, E.⁹ Mollejo, M.¹⁰ Papadaki, T.¹¹ Remstein, E.D.¹² Salar, A.¹³ Sole, F.¹⁴ Stamatopoulos, K.¹⁵ Thieblemont, C.¹⁶ Traverse-Glehen, A.¹⁷ Wotherspoon, A.¹⁸ Coiffier, B.¹⁹ Piris, M.A.²⁰ more..

3
- 84866875619
- Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: Development and validation on 593 cases
- Montalban C, Abraira V Arcaini L, et al. Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. Br J Haematol 2012;159:164-171.
- (2012) Br J Haematol , vol.159 , pp. 164-171
- Montalban, C.¹ Abraira Arcaini, V.L.²

4
- 78649477601
- Extensions of net reclassification improvement calculations to measure usefulness of newbiomarkers
- Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of newbiomarkers. Stat Med 2011;30:11-21.
- (2011) Stat Med , vol.30 , pp. 11-21
- Pencina, M.J.¹ D'Agostino, R.B.² Steyerberg, E.W.³

5
- 33745402382
- Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone
- DOI 10.1002/cncr.21931
- Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006;107:125-135. (Pubitemid 43941641)
- (2006) Cancer , vol.107 , Issue.1 , pp. 125-135
- Tsimberidou, A.M.¹ Catovsky, D.² Schlette, E.³ O'Brien, S.⁴ Wierda, W.G.⁵ Kantarjian, H.⁶ Garcia-Manero, G.⁷ Wen, S.⁸ Do, K.-A.⁹ Lerner, S.¹⁰ Keating, M.J.¹¹

6
- 46749123541
- Rituximab monotherapy is highly effective in splenic marginal zone lymphoma
- DOI 10.1002/hon.844
- Bennet M, Yegena S, Dave HP, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2008; 26: 114. (Pubitemid 351951341)
- (2008) Hematological Oncology , vol.26 , Issue.2 , pp. 114
- Bennett, M.¹ Yegena, S.² Dave, H.P.³ Schechter, G.P.⁴

7
- 34848837286
- Rituximab monotherapy is highly effective in splenic marginal zone lymphoma
- DOI 10.1002/hon.820
- Kalpadakis C, Pangalis GA, Dimopoulous MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2007; 25: 127-131. (Pubitemid 47507880)
- (2007) Hematological Oncology , vol.25 , Issue.3 , pp. 127-131
- Kalpadakis, C.¹ Pangalis, G.A.² Dimopoulou, M.N.³ Vassilakopoulos, T.P.⁴ Kyrtsonis, M.-C.⁵ Korkolopoulou, P.⁶ Kontopidou, F.N.⁷ Siakantaris, M.P.⁸ Dimitriadou, E.M.⁹ Kokoris, S.I.¹⁰ Tsaftaridis, P.¹¹ Plata, E.¹² Angelopoulou, M.K.¹³

8
- 84874381576
- Treatment of splenic marginal zone lymphoma with rituximab monotherapy: Progress report and comparison with splenectomy
- Kalpadakis C, Pangalis GT, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist 2013; 18: 190-197.
- (2013) Oncologist , vol.18 , pp. 190-197
- Kalpadakis, C.¹ Pangalis, G.T.² Angelopoulou, M.K.³

9
- 84867477542
- Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma
- Else M, Marin-Niebla A, de la Cruz F, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol 2012; 159: 322-328.
- (2012) Br J Haematol , vol.159 , pp. 322-328
- Else, M.¹ Marin-Niebla, A.² De La Cruz, F.³

10
- 77950302031
- Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL)
- Cervetti G, Galimberti S, Sordi E, et al. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol 2010;21:851-854.
- (2010) Ann Oncol , vol.21 , pp. 851-854
- Cervetti, G.¹ Galimberti, S.² Sordi, E.³

11
- 65749118869
- Non-pegylated lyposomal doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab (R-COMP) as initial treatment for patients with splenic marginal zone lymphoma (SMZL): GISL study
- Abstract 1292
- Iannitto E, Luminari S, Mammi C, et al. Non-pegylated lyposomal doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab (R-COMP) as initial treatment for patients with splenic marginal zone lymphoma (SMZL): GISL study. Blood 2007; 110(Suppl. 1): Abstract 1292.
- (2007) Blood , vol.110 , Issue.SUPPL. 1
- Iannitto, E.¹ Luminari, S.² Mammi, C.³

12
- 79953077312
- How i diagnose and treat splenic lymphomas
- Iannitto E, Tripodo C. How I diagnose and treat splenic lymphomas. Blood 2011; 117: 2585-2595.
- (2011) Blood , vol.117 , pp. 2585-2595
- Iannitto, E.¹ Tripodo, C.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.